SCHEMBL6800611

SCHEMBL6800611

O=c1c2cc(F)c(Cl)nc2n(-c2cccc(C(F)(F)F)c2)c(=O)n1OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.40
LMNA P02545 2/20 0.40
RGS4 P49798 2/20 0.40
RGS8 P57771 2/20 0.40
CYP1A2 P05177 1/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
GSR P00390 3/20 0.37
CCKBR P32239 1/20 0.37
THRB P10828 1/20 0.37
TSHR P16473 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MAT2A P31153 1/20 0.36
BRD9 Q9H8M2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799493 0.91 PPARD (0.35) CYP1A2MAOAMAOBTSHRMAT2A
SCHEMBL6798896 0.85 TSHR (0.38) CTSKLMNARGS4RGS8CYP1A2
SCHEMBL6798905 0.85 ALDH1A1 (0.42) CYP1A2TSHRMAPT
SCHEMBL6801352 0.83 ALDH1A1 (0.39) LMNACYP1A2TSHRMAPT
SCHEMBL6795249 0.83 PDE4A (0.41) LMNACYP1A2MAOAMAOBTSHR
SCHEMBL6797355 0.81 ALDH1A1 (0.43) LMNACYP1A2TSHRTP53MAPT
SCHEMBL6797211 0.79 GLA (0.42) CYP1A2TSHRTP53MAPT
SCHEMBL6801045 0.78 MAPT (0.41) LMNACYP1A2TSHRTP53MAPT
SCHEMBL6796950 0.77 ALDH1A1 (0.40) CYP1A2MAOAMAOBTSHR
SCHEMBL6803474 0.76 TRPV4 (0.36) TSHRMAT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US claimed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
EP-1028950-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 2000-08-23 EP claimed
WO-1999021840-A1 NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A CTSK 370/4885LMNA 3642/4885RGS4 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.